Neth J Med 57:2024 Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Chiola S, Gelardi F, Chiti A (2021) Long covid hallmarks on [ 18 F]FDG-pet/ct: a casecontrol study
,
A few commenters suggested alternatives to blanket penalties in public reporting, proposing the use of performance flags or annotations to highlight poor Safety of Care scores without reducing hospitals' Overall Hospital Quality Star Rating, thereby providing meaningful safety information while preserving rating comparability
#EliLilly #LLY #Retatrutide #ObesityTreatment #WeightLossDrug #Pharma #Biotech #Healthcare #ClinicalTrials #Phase3Trial #DiabetesCare #SleepApnea #MarketNews #StockMarket #Investing #FinancialMarkets #LinkedInFinance Eli Lilly's Retatrutide Shows Promising Weight Loss Results Eli Lilly rose 4.4% premarket to $1,181, extending Fridays record close, after Phase 3 data showed retatrutide delivered major weight loss and improved obesity-linked conditions